Severe immune thrombocytopenic purpura in critical COVID-19.

Link to article at PubMed

Related Articles

Severe immune thrombocytopenic purpura in critical COVID-19.

Int J Hematol. 2020 Jul 01;:

Authors: Lévesque V, Millaire É, Corsilli D, Rioux-Massé B, Carrier FM

COVID-19 is a new disease with many undescribed clinical manifestations. We report herein a case of severe immune thrombocytopenic purpura (ITP) in a critical COVID-19 patient. A patient presented a severe episode of immune thrombocytopenia (< 10 × 109/L) 20 days after admission for a critical COVID-19. This thrombocytopenia was associated with a life-threatening bleeding. Response to first-line therapies was delayed as it took up to 13 days after initiation of intravenous immunoglobulin and high-dose dexamethasone to observe an increase in platelet count. COVID-19 may be associated with late presenting severe ITP. Such ITP may also be relatively resistant to first-line agents. Hematological manifestations of COVID-19, such as the ones associated with life-threatening bleeding, must be recognized.

PMID: 32613314 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *